论文部分内容阅读
为评价病毒唑不同途径给药对小儿下呼吸道感染的疗效，采用随机对照方法对128例4岁以下小儿感染性喘病、喘息性支气管炎、毛细支气管炎及喘憋性肺炎病例进行了治疗和不良反应的观察研究。雾化吸入组65例，静滴用药组63例。结果表明雾化吸入组在止咳、平喘、退热及音吸收效果方面明显优于静脉用药组，住院天数也明显缩短。雾化给药对红细胞无不良反应，且有助于红细胞及血红蛋白的恢复。提示病毒吐雾化吸入用药治疗小儿下呼吸道感染更有利于直接控制呼吸道病毒感染，且疗效可靠，给药方便，并可避免长期静脉用药所引起的不良反应。
To evaluate the efficacy of different routes of ribavirin in the treatment of pediatric lower respiratory tract infections, a randomized controlled trial was conducted in 128 cases of infectious asthmatics, asthmatic bronchiolitis, bronchiolitis and asthmatic pneumonia in children under 4 years of age and Adverse reactions observed and studied. Inhalation inhalation group 65 cases, 63 cases of intravenous medication group. The results showed that the group inhaled aerosol inhalation in the cough, asthma, antipyretic and sound absorption effect was significantly better than the intravenous group, hospitalization days were significantly shortened. Nebulized administration does not adversely affect erythrocytes, and contribute to the recovery of red blood cells and hemoglobin. Prompt virus vomiting inhalation drug treatment of children with lower respiratory tract infection is more conducive to direct control of respiratory virus infection, and the curative effect is reliable, convenient administration, and can avoid long-term intravenous drug-induced adverse reactions.